In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH2) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 2, 2013, Pages 229-238

  Edelson, Jeffrey D ^a   Makhlina, Marie ^a   Silvester, Kevin R ^a   Vengurlekar, Shailesh S ^a   Chen, Xiaomei ^a   Zhang, Jie ^b   Koziol White, Cynthia J ^b   Cooper, Philip R ^b,e   Hallam, Trevor J ^a,d   Hay, Douglas W P ^c   Panettieri, Reynold A ^b  

^a Palatin Technologies   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Hay Drug Discovery Consulting   (United States)

^d Sutro Biopharma   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

2 agonists; ANP; ASM; Atrial natriuretic peptide; BNP; Brain natriuretic peptide; Bronchodilator; BSA; H; HEK cells; HPCLS; I.t.; Natriuretic peptide receptors; NEP; Neutral endopeptidase sensitivity; NK 2; NPR A; NPR B; NPR C; ORL1; PL 3994; SNP; Sst

Indexed keywords

ATRIAL NATRIURETIC FACTOR ANTAGONIST; BRONCHODILATING AGENT; CARBACHOL; CYCLIC GMP; MEMBRANE METALLOENDOPEPTIDASE; METHACHOLINE; PL 3994; UNCLASSIFIED DRUG; ATRIAL NATRIURETIC FACTOR RECEPTOR; BRAIN NATRIURETIC PEPTIDE; CYCLOPEPTIDE; NATRIURETIC PEPTIDE RECEPTOR A; PIPERAZINE DERIVATIVE; PL-3994;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BRONCHODILATING ACTIVITY; BRONCHOSPASM; CONCENTRATION RESPONSE; ENZYME DEGRADATION; EXPERIMENTAL DOG; EXPERIMENTAL GUINEA PIG; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SMOOTH MUSCLE; TRACHEA; ANIMAL; CELL STRAIN HEK293; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; GUINEA PIG; MALE; METABOLISM; PHYSIOLOGY; RAT; WISTAR RAT;

ANIMALS; BRONCHODILATOR AGENTS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; HEK293 CELLS; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; NEPRILYSIN; PEPTIDES, CYCLIC; PIPERAZINES; RATS; RATS, WISTAR; RECEPTORS, ATRIAL NATRIURETIC FACTOR; TRACHEA;

EID: 84874564096     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.11.001     Document Type: Article

References (45)

1. Panettieri R.A., Covar R., Grant E., Hilyer E.V., Bacharier L. Natural history of asthma: persistence versus progression - does the beginning predict the end?. J Allergy Clin Immunol 2008, 121:607-613.
2. Clark D.J., Lipworth B.J. Dose-response of inhaled drugs in asthma. Update Clin Pharmacokinet 1997, 32:58-74.
3. Shore S.A., Drazen J.M. Beta-agonists and asthma: too much of a good thing?. J Clin Invest 2003, 112:495-497.
4. Nelson H.S. Is there a problem with inhaled long-acting beta-adrenergic agonists?. J Allergy Clin Immunol 2006, 117:3-16. [quiz 17].
5. Sharma S., Litonjua A.A., Tantisira K.G., Fuhlbrigge A.L., Szefler S.J., Strunk R.C., et al. Clinical predictors and outcomes of consistent bronchodilator response in the childhood asthma management program. J Allergy Clin Immunol 1989, 122:921-928.
6. Ortega V.E., Peters S.P. Beta-2 adrenergic agonists: focus on safety and benefits versus risks. Curr Opin Pharmacol 2010, 10:246-253.
7. Rodrigo G.J., Castro-Rodriguez J.A. Safety of long-acting beta agonists for the treatment of asthma: clearing the air. Thorax 2012, 67(4):342-349.
8. Pandey K.N. Biology of natriuretic peptides and their receptors. Peptides 2005, 26:901-932.
9. Potter L.R., Abbey-Hosch S., Dickey D.M. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006, 27:47-72.
10. Potter L.R., Yoder A.R., Flora D.R., Antos L.K., Dickey D.M. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handbook Exp Pharmacol 2009, 191:341-366.
11. Anand-Srivastava M.B. Natriuretic peptide receptor-C signaling and regulation. Peptides 2005, 6:1044-1059.
12. Barr C.S., Rhodes P., Struthers A.D. C-type natriuretic peptide. Peptides 1996, 17(7):1243-1251.
13. Perreault T., Gutkowska J. Role of atrial natriuretic factor in lung physiology and pathology. Am J Respir Crit Care Med 1995, 151:226-242.
14. Rubinstein I., Reiss T.F., Gardner D.G., Liu J., Bigby B.G., Boushey H.A. Effect of exercise, hyperpnea, and bronchoconstriction on plasma atrial natriuretic peptide. J Appl Physiol 1989, 67(6):2565-2570.
15. Ohbayashi H., Suito H., Takagi K. Compared effects of natriuretic peptides on ovalbumin-induced asthmatic model. Eur J Pharmacol 1998, 346:55-64.
16. Torphy T.J. Phosphodiesterase Isozymes. Molecular targets for novel antiasthma agents. Am Rev Resp Crit Care Med 1998, 157:351-370.
17. Hamad A.M., Johnson S.R., Knox A.J. Antiproliferative effects of NO and ANP in cultured human airway smooth muscle. Am J Physiol 1999, 277(5 Pt 1):L910-L918.
18. Hamad A.M., Clayton A., Islam B., Knox A.J. Guanylyl cyclases, nitric oxide, natriuretic peptides, and airway smooth muscle function. Am J Physiol Lung Cell Mol Physiol 2003, 285(5):L973-L983.
19. Mohapatra S.S., Lockey R.F., Vesely D.L., Gower W.R. Natriuretic peptides and genesis of asthma: an emerging paradigm?. J Allergy Clin Immunol 2004, 114:520-526.
20. Mohapatra S.S. Role of natriuretic peptide signaling in modulating asthma and inflammation. Can J Physiol Pharmacol 2007, 85:754-759.
21. Lima J., Mohapatra S., Feng H., Lockey R., Jena P.K., Castro M., et al. A polymorphism in the NPPA gene associates with asthma. Clin Exp Allergy 2008, 38:1117-1123.
22. Rogers A.J., Raby B.A., Lasky-Su J.A., Murphy A., Lazarus R., Klanderman B.J., et al. Assessing the reproducibility of asthma candidate gene associations, using genomewide data. Am J Respir Crit Care Med 2009, 179:1084-1090. [Erratum in: Am J Respir Crit Care Med 2010;181:96].
23. O'Donnell M., Garippa R., Welton A.F. Relaxant activity of atriopeptins in isolated guinea pig airway and vascular smooth muscle. Peptides 1985, 6(4):597-601.
24. Fernandes L.B., Preuss J.M.H., Goldie R.G. Epithelial modulation of the relaxant activity of atriopeptides in rat and guinea-pig tracheal smooth muscle. Eur J Pharmacol 1992, 212:187-194.
25. Candenas M.-L., Naline E., Puybasset L., Devillier P., Advenier C. Effect of atrial natriuretic peptide and on atriopeptins on the human isolated bronchus. Comparison with the reactivity of the guinea-pig isolated trachea. Pulmon Pharmacol 1991, 4:120-125.
26. Hulks G., Jardine A., Connell J.M.C., Thomson N.C. Bronchodilator effect of atrial natriuretic peptide in asthma. Br Med J 1989, 229:1081-1082.
27. Chanez P., Mann C., Bousquet J., Chabrier P.E., Godard P., Braquet P., et al. Atrial natriuretic factor (ANF) is a potent bronchodilator in asthma. J Allergy Clin Immunol 1990, 86:321-324.
28. Angus R.M., McCallum M.J.A., Hulks G., Thomson N.C. Bronchodilator, cardiovascular, and cyclic guanylyl monophosphate response to high-dose infused atrial natriuretic peptide in asthma. Am Rev Respir Dis 1993, 147:1122-1125.
29. Hulks G., Thomson N.C. High dose inhaled atrial natriuretic peptide is a bronchodilator in asthmatic subjects. Eur Respir J 1994, 7(9):1593-1597.
30. Angus R.M., Millar E.A., Chalmers G.W., Thomson N.C. Effect of inhaled atrial natriuretic peptide and a neutral endopeptidase inhibitor on histamine-induced Bronchoconstriction. Am J Respir Crit Care Med 1995, 151(6):2003-2005.
31. Angus R.M., Millar E.A., Chalmers G.W., Thomson N.C. Effect of inhaled thiorphan, a neutral endopeptidase inhibitor, on the bronchodilator response to inhaled atrial natriuretic peptide (ANP). Thorax 1996, 51(1):71-74.
32. Cooper P.R., Panettieri R.A. Steroids completely reverse albuterol-induced beta(2)-adrenergic receptor tolerance in human small airways. J Allergy Clin Immunol 2008, 122:734-740.
33. Cooper P.R., Lamb R., Day N.D., Branigan P.J., Kajekar R., San Mateo L., et al. TLR3 activation stimulates cytokine secretion without altering agonist-induced human small airway contraction or relaxation. Am J Physiol Lung Cell Mol Physiol 2009, 297:L530-L537.
34. Bagarozzi D.A., Potempa J., Travis J. Purification and characterization of an arginine-specific peptidase from ragweed (Ambrosia artemisiifolia) pollen. Am J Respir Cell Mol Biol 1998, 3:363-369.
35. Labat C., Norel X., Benveniste J., Brink C. Vasorelaxant effects of atrial peptide II on isolated human pulmonary muscle preparations. Eur J Pharmacol 1988, 150:397-400.
36. Nally J.E., Clayton R.A., Thomson N.C., McGrath J.C. The interaction of human atrial natriuretic peptide (ANP) with salbutamol, sodium nitroprusside and isosorbide dinitrate in human bronchial smooth muscle. Br J Pharmacol 1994, 113:1328-1332.
37. Matera M.G., Calzetta L., Parascandolo V., Curradi G., Rogliani P., Cazzola M. Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. Pulmon Pharmacol Therap 2009, 22:478-482.
38. Akerman M.J., Yaegashi M., Khiangte Z., Murugan A.T., Abe O., Marmur J.D. Bronchodilator effect of infused B-type natriuretic peptide in asthma. Chest 2006, 130(1):66-72.
39. Bianchi C., Gutkowska J., Thibault G., Garcia R., Genest J., Cantin M. Radioautographic localization of 125I-atrial natriuretic factor (ANF) in rat tissues. Histochemistry 1985, 82:441-452.
40. Nadel J.A., Borson D.B. Modulation of neurogenic inflammation by neutral endopeptidase. Am Rev Respir Dis 1991, 143(3 Part 2):S33-S36.
41. Matera M.G., Calzetta L., Passeri D., Facciolo F., Rendina E.A., Page C., et al. Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi. Br J Pharmacol 2011, 163:1740-1754.
42. McKie P.M., Sangaralingham S.J., Burnett J.C. CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease. Curr Heart Fail Rep 2010, 7:93-99.
43. McKie P.M., Ichiki T., Burnett J.C. M-Atrial natriuretic peptide: a novel antihypertensive protein therapy. Curr Hyper Rep 2012, 14:62-69.
44. Dickey D.M., Burnett J.C., Potter L.R. Novel bifunctional natriuretic peptides as potential therapeutics. J Biol Chem 2008, 283:35003-35009.
45. Dickey D.M., Yoder A.R., Potter L.R. A familial mutation renders atrial natriuretic peptide resistant to proteolytic degradation. J Biol Chem 2009, 284:19196-19202.